William P Tew

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
  2. doi request reprint Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Curr Treat Options Oncol 14:1-11. 2013
  3. doi request reprint Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:358-66. 2010
  4. doi request reprint Ovarian cancer in older women
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 35:582-9. 2008
  5. doi request reprint Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Joyce N Barlin
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 125:621-4. 2012
  6. doi request reprint Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer
    Sarah A Milgrom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 130:436-40. 2013
  7. pmc CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer
    Elizabeth Won
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 23:1022-8. 2013
  8. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
  9. doi request reprint Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
    John P Diaz
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:335-9. 2010
  10. doi request reprint The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010

Collaborators

Detail Information

Publications24

  1. pmc Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
    ..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
  2. doi request reprint Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Curr Treat Options Oncol 14:1-11. 2013
    ..As the field of geriatric oncology evolves and prospective trials tailored to older women with ovarian cancer are developed, specific guidelines will ultimately assist in these difficult decisions...
  3. doi request reprint Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:358-66. 2010
    ..To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent...
  4. doi request reprint Ovarian cancer in older women
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 35:582-9. 2008
    ....
  5. doi request reprint Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Joyce N Barlin
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 125:621-4. 2012
    ..We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified outpatient IP regimen...
  6. doi request reprint Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer
    Sarah A Milgrom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 130:436-40. 2013
    ..One regimen is concurrent external beam pelvic irradiation (RT) and cisplatin, then carboplatin/paclitaxel. This study reports an institutional experience using this approach in stage III (FIGO 2009) endometrial cancer...
  7. pmc CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer
    Elizabeth Won
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 23:1022-8. 2013
    ..CA125 is a sensitive biomarker for tumor burden. The study evaluates the association between CA125, geriatric assessment (GA), and treatment toxicity...
  8. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  9. doi request reprint Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
    John P Diaz
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:335-9. 2010
    ..The objective of this study was to examine the incidence and management of bevacizumab-associated gastrointestinal (GI) perforations in patients with recurrent ovarian carcinoma...
  10. doi request reprint The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  11. doi request reprint Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies
    Vaagn Andikyan
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 23:923-8. 2013
    ..We conducted a retrospective review to evaluate the feasibility of administering adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies...
  12. pmc Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
    ..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed...
  13. doi request reprint Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters
    Stephanie L Wethington
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 23:1092-8. 2013
    ..Tumor size greater than 2 cm has been considered a contraindication, and those patients denied trachelectomy. We report our trachelectomy experience with tumors measuring 2 to 4 cm...
  14. ncbi request reprint Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 106:381-7. 2007
    ..The objective of this study was to compare the response to platinum-taxane chemotherapy and subsequent outcomes between patients older and younger than 65 years of age with stages IIIC-IV epithelial ovarian cancer (EOC)...
  15. doi request reprint Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 111:265-70. 2008
    ..The treatment of FIGO stage IB2 cervical cancer is controversial. Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer...
  16. doi request reprint Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
    ..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
  17. ncbi request reprint Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience
    Aliza L Leiser
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 105:657-61. 2007
    ....
  18. doi request reprint Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer
    Karin K Shih
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 128:535-9. 2013
    ..The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with or without chemotherapy in high-risk endometrial cancer...
  19. doi request reprint A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer
    Dennis S Chi
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncologist 14:835-9. 2009
    ..To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer...
  20. doi request reprint Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study
    William P Tew
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 120:335-43. 2014
    ....
  21. pmc Use of complementary medications among older adults with cancer
    Ronald J Maggiore
    Department of Medicine, Sections of Geriatrics Palliative Medicine and Hematology Oncology, University of Chicago Medical Center, Chicago, Illinois, USA
    Cancer 118:4815-23. 2012
    ..The objective of this study was to evaluate the prevalence of complementary medication use and to identify the factors associated with its use among older adults with cancer...
  22. ncbi request reprint Targeted therapies for esophageal cancer
    William P Tew
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA
    Oncologist 10:590-601. 2005
    ..This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma...
  23. pmc Doublet chemotherapy in the elderly patient with ovarian cancer
    Min Y Teo
    Department of Medical Oncology, Cork Mercy University Hospitals, Cork, Ireland
    Oncologist 17:1450-60. 2012
    ..Geriatric assessment is an important component of decision making. Prospective studies are needed to develop strategies to determine the optimal treatment for older patients with ovarian cancer...
  24. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....